OTCMKTS:CBBT Cerebain Biotech (CBBT) Stock Price, News & Analysis $0.0009 0.00 (0.00%) As of 09/2/2021 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cerebain Biotech Stock (OTCMKTS:CBBT) Get Cerebain Biotech alerts:Sign Up Key Stats Today's Range$0.0008▼$0.001050-Day Range N/A52-Week Range$0.00▼$0.47Volume2.04 million shsAverage Volume11.21 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cerebain Biotech Corp. is a biomedical company, which engages in the creation and clinical development of a minimally invasive implantable device. It focuses on the discovery of products for the treatment of Alzheimer's disease utilizing Omentum. The company was founded on December 18, 2007 and is headquartered in Costa Mesa, CA. Read More Receive CBBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerebain Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBBT Stock News HeadlinesCBBT expansion back in motion after crews discover centuries-old anchor, halting project for monthsAugust 29, 2024 | msn.comImClone Founder Waksal Forming New Biotech VentureOctober 28, 2023 | thestreet.com1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to help regular investors generate enough income to become financially independent… Without taking on excessive amounts of risk. I’m talking about having the opportunity to collect $500 on Monday… $563 on Wednesday… Then as much as $625 on Friday.October 8 at 2:00 AM | Base Camp Trading (Ad)Duopharma Biotech Bhd (DUOP)September 19, 2023 | investing.comFormer Google AI expert raises $100mn for biotech start-upSeptember 10, 2023 | ft.comPharmAla Biotech to supply University of California Clinical Trial with LaNeo™ MDMAOctober 6, 2022 | finance.yahoo.comJapan Biotech Startups Directory 2022September 15, 2022 | finance.yahoo.comCerebain Biotech Closes Share Exchange Agreement With PKG, Inc.September 20, 2021 | finance.yahoo.comSee More Headlines CBBT Stock Analysis - Frequently Asked Questions How have CBBT shares performed this year? Cerebain Biotech's stock was trading at $0.0009 at the start of the year. Since then, CBBT shares have increased by 0.0% and is now trading at $0.0009. How do I buy shares of Cerebain Biotech? Shares of CBBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cerebain Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cerebain Biotech investors own include Bionano Genomics (BNGO), Aurora Cannabis (ACB), HUMBL (HMBL), Carnival (CCL), Canopy Growth (CGC), Enzolytics (ENZC) and SNDL (SNDL). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryWholesale Current SymbolOTCMKTS:CBBT CIKN/A Webwww.cerebain.com Phone(714) 371-4109FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:CBBT) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredAn Early Move On The Next Shift In CoinLitecoin is already processing 500,000+ daily transactions, integrated with PayPal and Revolut, and now one fi...Market Tactic | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerebain Biotech Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerebain Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
